Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

For women, ovarian cancer is one of the most feared of all diagnoses. Sneaking up silently, often with few symptoms, the ...

We knew we had something interesting with T3p, a single small RNA found in breast cancer but absent from normal tissue.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...

The discovery began, as many breakthroughs do, with an observation that didn’t quite make sense. In 1948, two French researchers, Paul Mandel and Pierre Métais, published a little-noticed paper in a ...

After being described in 2018, researchers knew they had something interesting with T3p, a single small RNA found in breast ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. It should be noted that the Galleri test not currently ...